Patients treated with dasatinib for newly diagnosed chronic myeloid leukemia experienced greater health care resource utilization and associated costs due to infection than patients treated with nilotinib.
Patients with acute leukemia exhibited a high rate of venous thromboembolism, along with high recurrence rates.
Prognosis and cure perceptions among older adults with acute myeloid leukemia often diverge from oncologist estimates.
A prophylactic therapy is effective in preventing treatment-associated mild-to-moderate bone pain in breast cancer.
Elevated C-reactive protein prior to autologous stem cell transplantation identifies a high-risk population in patients with multiple myeloma.
The US Food and Drug Administration has approved a next-generation sequencing assay that may be used as a companion diagnostic for therapy selection for solid tumors.
The US FDA has granted approval to a biosimilar for trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer and metastatic stomach cancer.
The US FDA has granted approval to the first breakthrough-designated, next generation sequencing-based test that detects mutations in 324 genes in any solid tumor type.
Maintenance therapy with a specific drug is associated with superior OS and PFS in patients who receive high-dose therapy followed by ASCT for MCL.
Hospital systems can reduce drug diversion among employees through the implementation of a multidisciplinary diversion reduction program.